Check Out What’s New at Goldfinch

Filter by year:

11.19.20

Goldfinch Bio Announces Appointment of Robin A. Walker, J.D., as Chief Legal Officer

10.22.20

Goldfinch Bio Presents Clinical Data from Phase 1 Trial Supporting Advancement of GFB-887 as a Precision Medicine for Patients with Kidney Diseases

10.14.20

Goldfinch Bio Honored by Goldman Sachs for Entrepreneurship

10.13.20

Goldfinch Bio Announces Upcoming Presentation of Phase 1 Clinical Data for Lead Precision Kidney Therapeutic Candidate, GFB-887, and Expansion of Scientific Leadership Team

10.07.20

Academic and Industry Collaborative Study, including Goldfinch Bio, Demonstrates Benefit of Proteinuria Reduction on Kidney Survival in Patients with Focal Segmental Glomerulosclerosis (FSGS)

Check out our new interview series, The Feeder. We’re speaking with people impacted by kidney disease, and a wide range of experts who are driving change, innovation and hope in the kidney space.

March 2021

In this episode of The Feeder, Dr. Liron Walsh, Vice President of Translational & Clinical Nephrology at Goldfinch Bio, speaks with Dr. Kirk Campbell, an Associate Professor of Medicine, Director of the Nephrology Fellowship Program, and the Vice Chair for Diversity and Inclusion at the Icahn School of Medicine at Mount Sinai, about his work and the evolving innovation landscape in nephrology.

February 2021

As part of our interview series, The Feeder, Jill H., who was diagnosed with focal segmental glomerulosclerosis, or FSGS, at age 14 speaks with our President & CEO Tony Johnson, M.D., about living with and managing this disease, including her experience with dialysis and kidney transplants.